Article Text

Download PDFPDF
Letter
Association between proton pump inhibitor use and mortality in patients with hepatocellular carcinoma receiving tyrosine kinase inhibitor

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Correction notice This article has been corrected since it published Online First. Dr Lee's name has been corrected.

  • Contributors Chun-YW and HJH had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Study conception and design; drafting of the manuscript; study supervision: Chun-YW. Acquisition, analysis or interpretation of data: Chun-YW, HJH and Chen-YW. Critical revision of the manuscript for important intellectual content: all authors. Statistical analysis: HJH and Chun-YW. Obtained funding: Chun-YW, HJH, Chen-YW and Y-JC. Administrative, technical or material support: Chun-YW, T-YL and Y-CH.

  • Funding This work was supported in part by National Yang-Ming University (E107F-M01-0503), the Handa Pharmaceuticals (YM108C058) and Ministry of Science and Technology (MOST 109-2327-B-010-003-), Taiwan.

  • Competing interests None declared.

  • Patient and public involvement Patients and/or the public were involved in the design, or conduct, or reporting, or dissemination plans of this research. Refer to the Methods section for further details.

  • Provenance and peer review Not commissioned; externally peer reviewed.